AG1321001

AG1321001 is an investigational drug developed as an anti-tussive (cough suppressant) agent. It has been evaluated in clinical trials for its safety and efficacy in patients with chronic cough, including confirmatory therapeutic studies. The drug is formulated as a capsule for oral administration and was developed by Ahn-Gook Pharmaceuticals, a South Korean pharmaceutical company. Its precise mechanism of action has not been publicly disclosed, and there is no evidence it belongs to any well-known class of anti-tussive agents such as opioid receptor agonists or P2X3 antagonists. The primary indication under investigation is chronic cough[1][2][7].